Activation and in vitro expansion of tumor‐reactive T Lymphocytes from lymph nodes draining human primary breast cancers

Sk, Hoover; Jl, Frank; McCrady, Carl W.; Jg, McKinnon; Hd, Bear

doi:10.1002/jso.2930460210

Cited by 12 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some breast cancer patients, tumor-reactive T-lymphocytes expanded from regional lymph nodes demonstrate tumor-specific responses [40,41]. The primary obstacle to adoptive immunotherapy has been generating sufficient numbers of tumor-specific cells for transfer, as there are few among the peripheral blood lymphocytes and the harvesting of tumor infiltrating lymphocytes from breast tumors is technically challenging.…”

Section: Cryosurgery Surgerymentioning

confidence: 99%

Immunologic response to cryoablation of breast cancer

Sabel

Nehs

et al. 2005

Breast Cancer Res Treat

158

View full text Add to dashboard Cite

Public reporting burden for tNs collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this coNootion of infomtation. Send comments regarding this burden estimate or any other aspect of this collection of information, indutSng suggestions for reducing this burden to Washington Headquarters Services, Directorate for Infomiation Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Papenirork Reduction Prc^ecl (0704-0188),

show abstract

Section: Cryosurgery Surgerymentioning

confidence: 99%

Immunologic response to cryoablation of breast cancer

Sabel

Nehs

et al. 2005

Breast Cancer Res Treat

158

View full text Add to dashboard Cite

show abstract

“…An alternate source may be located in the tumor-draining lymph nodes (TDLNs). Tumor-reactive T lymphocytes can be expanded from regional lymph nodes in patients who have breast cancer; in some patients, these T cells demonstrate a tumor-specific response [71]. Okino et al [72] obtained lymphocytes from regional lymph nodes and peripheral blood from patients who had breast cancer with liver metastases.…”

Section: Adoptive Immunotherapymentioning

confidence: 99%

Immunologic approaches to breast cancer treatment

Sabel¹,

Nehs²

2005

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

The need for less toxic adjuvant therapies and a better understanding of the processes by which the immune system can eradicate micrometastatic disease has generated significant interest in breast cancer immunotherapy. There are many potential approaches to stimulating an immune response against a tumor, each with relative advantages and disadvantages in regards to cost, immunogenicity, and clinical applicability in treating breast cancer. This article will review the mechanisms by which the immune system can recognize and eradicate neoplastic cells and the various methods of stimulating an anti-tumor immune response. Obstacles to the clinical effectiveness of immunotherapies in breast cancer are also discussed.

show abstract

Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody

Triozzi

Kim

Aldrich

et al. 1994

Cancer

View full text Add to dashboard Cite

Background. Lymph node lymphocytes vary in their responsiveness to tumor. A technique has been developed that uses radiolabeled monoclonal antibody (MoAb) against the tumor‐associated mucin, TAG‐72, and a gamma‐detecting probe by which lymph nodes containing microscopic tumor and/or shed TAG‐72 can be identified in vivo. The immunologic characteristics of these lymph nodes were examined. Methods. Patients with colon cancer received 125I‐labeled MoAb CC49 by intravenous injection preoperatively. During laparotomy lymph nodes that appeared normal on inspection and palpation but which contained radiolabeled MoAb were identified using a hand‐held gamma‐detecting probe. These lymph nodes and other lymph node and tumor specimens were resected for analysis. Results. Lymph nodes identified by the probe were found by immunohistochemical studies to contain microscopic tumor and/or shed antigen associated with germinal centers. They were characterized by greater CD4+:CD8+ ratios, rates of expansion, and cytolytic activity compared with lymphocytes from lymph nodes with macroscopic tumor, noninvolved lymph nodes, and tumors. All lymph node lymphocytes identified by the probe demonstrated significant proliferative responses to autologous tumor and, in contrast to lymphocytes from noninvolved lymph nodes, significant proliferative responses to allogeneic TAG‐72+ tumor cells and to soluble TAG‐72+ mucin. Conclusions. By locating lymph nodes with microscopic tumor and/or shed antigen, the use of radiolabeled MoAb in vivo can be used to reproducibly identify tumor‐reactive lymph node lymphocytes. This technique may be useful in identifying cells for use in adoptive immunotherapy programs and in studying the regulation of immune responses in vivo.

show abstract

Activation and in vitro expansion of tumor‐reactive T Lymphocytes from lymph nodes draining human primary breast cancers

Cited by 12 publications

References 38 publications

Immunologic response to cryoablation of breast cancer

Immunologic response to cryoablation of breast cancer

Immunologic approaches to breast cancer treatment

Localization of tumor-reactive lymph node lymphocytes in vivo using radiolabeled monoclonal antibody

Contact Info

Product

Resources

About